1050602-61-3

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-N-cyclopropyl-5-(trifluoroMethyl)pyriMidin-4-aMine is used as a drug candidate for its potential biological activities. Its specific chemical structure allows it to interact with biological targets, which may lead to the development of new treatments for various diseases and conditions.
Used in Drug Synthesis:
In the pharmaceutical industry, 2-Chloro-N-cyclopropyl-5-(trifluoroMethyl)pyriMidin-4-aMine is also used as an intermediate in the synthesis of other pharmaceuticals. Its unique structure can be further modified or used as a building block to create more complex molecules with specific therapeutic effects.
Used in Research and Development:
2-Chloro-N-cyclopropyl-5-(trifluoroMethyl)pyriMidin-4-aMine serves as a valuable compound in the ongoing research and development efforts within the pharmaceutical sector. Its properties and potential applications are being explored to better understand its mechanisms of action and to identify new uses in medicine.

Upstream product

• 3932-97-6 2,4-dichloro-5-trifluoromethylpyrimidine 
• 765-30-0 Cyclopropylamine 

Downstream Products

• 1401423-22-0 (4-(4-(cyclopropylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-2-fluoro-5-methoxyphenyl)(morpholino)methanone 
• 1401423-44-6 C₁₆H₁₄F₄N₄O₃ 

Relevant academic research and scientific papers

Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer

Inhibition of autophagy, the major cellular recycling pathway in mammalian cells, is a promising strategy for the treatment of triple-negative breast cancer (TNBC). We previously reported SBI-0206965, a small molecule inhibitor of unc-51-like autophagy activating kinase 1 (ULK1), which is a key regulator of autophagy initiation. Herein, we describe the design, synthesis, and characterization of new dual inhibitors of ULK1 and ULK2 (ULK1/2). One inhibitor, SBP-7455 (compound 26), displayed improved binding affinity for ULK1/2 compared with SBI-0206965, potently inhibited ULK1/2 enzymatic activity in vitro and in cells, reduced the viability of TNBC cells and had oral bioavailability in mice. SBP-7455 inhibited starvation-induced autophagic flux in TNBC cells that were dependent on autophagy for survival and displayed synergistic cytotoxicity with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib against TNBC cells. These data suggest that combining ULK1/2 and PARP inhibition may have clinical utility for the treatment of TNBC.

Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (PET) imaging for LRRK2

A method for positron emission tomography (PET) imaging of LRRK2 in tissue of a subject, the method comprising: administering a compound of formula I, formula II or formula III, or a pharmaceutically acceptable salt thereof to the subject, wherein the com

2-PHENYLAMINOPYRIMIDINE DERIVATIVES AS KINASE LRRK2 MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE

Specific Compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein m, X, R, R2, R3, R, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE

Compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3 and A are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease

FLUORINE-18 AND CARBON-11 LABELED RADIOLIGANDS FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING FOR LRRK2

A method for positron emission tomography (PET) imaging of LRRK2 in the tissue of a subject, the method comprising: administering a compound of formula (I), formula (II) or formula (III), or a pharmaceutically acceptable salt thereof to the subject, where

Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors

There is a high demand for potent, selective, and brain-penetrant small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) to test whether inhibition of LRRK2 kinase activity is a potentially viable treatment option for Parkinson's disease patients. Herein we disclose the use of property and structure-based drug design for the optimization of highly ligand efficient aminopyrimidine lead compounds. High throughput in vivo rodent cassette pharmacokinetic studies enabled rapid validation of in vitro-in vivo correlations. Guided by this data, optimal design parameters were established. Effective incorporation of these guidelines into our molecular design process resulted in the discovery of small molecule inhibitors such as GNE-7915 (18) and 19, which possess an ideal balance of LRRK2 cellular potency, broad kinase selectivity, metabolic stability, and brain penetration across multiple species. Advancement of GNE-7915 into rodent and higher species toxicity studies enabled risk assessment for early development.

Heterocyclically Substituted Anilinopyrimidines

Heterocyclically substituted anilinopyrimidines of the formula (I) in which R1 to R12 and E1, E2, E3, L1, Y, Z and L2 have the meanings given in the description, and agrochemically active salts thereof, their us

Alkoxy- and Alkylthio-Substituted Anilinopyrimidines

Alkoxy- and alkylthio-substituted anilinopyrimidines of the formula (I) in which R1 to R14 and E1, E2, E3, X and Y have the meanings given in the description, and agrochemically active salts thereof, their use, and methods and compos

Heterocyclically Substituted Anilinopyrimides

Heterocyclically substituted anilinopyrimidines of the formula (I) in which R1 to R10 and L1, L2, E1, E2, E3, Y and Z have the meanings given in the description, and agrochemically active salts thereof, their use and also methods and compositions for controlling phytopathogenic harmful fungi in and/or on plants or in and/or on seed of plants, processes for preparing such compositions and treated seed and also their use for controlling phytopathogenic harmful fungi in agriculture, horticulture and forestry, in the protection of materials and in the domestic and hygiene field. The present invention furthermore relates to a process for preparing heterocyclically substituted anilinopyrimidinenes of the formula (I).

DIAMINOPYRIMIDINES AS FUNGICIDES

Use of diaminopyrimidines of the formula (I) in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and X1, X2 an